1. Home
  2. Research and Funding
  3. Current Funding Opportunities
  4. Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)

Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites a cooperative agreement application to continue the mission of the existing Human Pancreas Analysis Program (HPAP). This FOA will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; collection, processing and multimodal analysis of human pancreatic tissues; and biological database building, curation and management, that will be tasked to: 1) identify, collect and intensively characterize primary pancreatic tissues from patients with type 1 diabetes (T1D) or at risk of developing the disease, as well as age-matched controls; and 2) analyze, organize and share the data resulting from the study of these tissues through the existing PANC DB open-access resource database. HPAP is a component of the Human Islet Research Network or HIRN. HIRN was created in 2014 to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional human beta cell mass.

Funding Opportunity Details

RFA-DK-20-016
None

Xujing Wang, Ph.D.

Key Dates

10/10/2020

October 10, 2020

November 10, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on thisdate.

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.